Which CHO cell is the right CHO cell?

Dr Louis Boon offers guidance on how to select the best CHO cell for the upstream bioprocessing of biologics. He also explains how automation can aid monoclonality and why the most efficient approach during the development of biological drugs is to utilise an established cell line platform.

CHO cell line development

Since the approval of the first biotherapeutic in the 1980s, there has been a consistent growth in the biologics market, the technology associated with it and quite notably, the bioprocessing used in their production. Unlike small molecule drugs, biologics cannot be chemically synthesised. Instead, they must be produced by living cells in bioreactors or fermenters. The earliest and most straightforward biologics were produced and hosted in microbial systems, particularly E. coli. The increasing complexity of the protein molecules introduced a shift to yeast cells as hosts. Subsequently, to produce monoclonal antibodies (mAbs), mammalian production platforms were established. mAbs are the most advanced, valuable and sophisticated class of biotherapeutics. They are complex proteins with defined tertiary structures, including an N-linked glycan on the constant domain of the heavy chain, requiring specific post-translation modifications (PTMs) and a cellular system to perform complex protein folding and glycosylation.

    To read this article in full, please complete the form below:


    This specialist content is provided to you free-of-charge thanks to the kind support of Sphere Fluidics

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend